drugset / Trial / NCT06383078
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Phase 2
Not yet recruiting
120 enrolled
The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.
Timeline
- Start
- 2024-04-20
- Primary completion
- 2027-03-01
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HR070803 | Unknown | 60 mg/m2 | — |
| Comparator | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | — | Oral |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
Indications
No indication recorded.